# A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

> **NCT00972309** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- Prostate Specific Antigens
- Prostate Neoplasms

## Interventions

- **BIOLOGICAL:** T-cell receptor alternate reading frame protein (TARP) peptide vaccine
- **BIOLOGICAL:** T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine

## Key facts

- **NCT ID:** NCT00972309
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-11
- **Primary completion:** 2015-02-04
- **Final completion:** 2015-02-04
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00972309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00972309, "A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00972309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*